Pay-for-Performance Deals

By Business Review Editor

Pharma Deals Review: Vol 2008 Issue 91 (Table of Contents)

Published: 8 Jan-2008

DOI: 10.3833/pdr.v2008.i91.238     ISSN: 1756-7874

Section: General



In October 2007, Janssen-Cilag proposed the UK National Health Service to refund costs for Velcade® (bortezomib) in patients whose tumors do not shrunk sufficiently after a specified treatment period...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details